-
Cardiff City lose compensation case over Emiliano Sala death
-
Several French far-right mayors take down EU flags
-
Air Canada CEO to retire after row over English-only condolence message
-
Oil rises on Trump's Iran threats, stocks take cue on talks
-
Syrian leader pledges to work with Germany on migration, recovery
-
AI agent future is coming, OpenClaw creator tells AFP
-
Cardiff lose 122 mn euro compensation case over Emiliano Sala death
-
Tuchel defends Rice and Saka after England withdrawals
-
G7 ministers tackle economic fallout of Mideast war
-
Tottenham close in on De Zerbi as next boss - reports
-
Kenya's former NY marathon champion Korir gets 5-year doping ban
-
Lukaku says 'could never turn back on Napoli' after treatment row
-
Syrian leader visits Germany to talk war, recovery, refugees
-
Renault says developing ground-based military drone
-
Iran hangs two 'political prisoners' from banned opposition: activists
-
Russia expels UK diplomat on spying allegations
-
Premier League fans back call to scrap VAR
-
Italy hoping to scale World Cup 'Everest' ahead of Bosnia play-off showdown
-
Japan's cherry blossom season dazzles locals and tourists
-
EU ups mackerel quotas to match UK despite overfishing concerns
-
Crude rises, stocks drop as Houthi attacks escalate Iran war
-
Australian Rules player banned for wiping blood on face of opponent
-
Sheep culls put pressure on Greek feta cheese production
-
One man, his dog, and ChatGPT: Australia's AI vaccine saga
-
Israel PM restores access after Latin Patriarch blocked from Holy Sepulchre
-
Israel strikes Tehran as Trump says Iran deal may be reached 'soon'
-
Italy chase World Cup spot as Kosovo bid to make debut
-
Myanmar paves way for junta chief to become civilian president
-
'Long live the shah': Iranian diaspora back war at Washington rally
-
Taiwan opposition leader accepts Xi's invitation to visit China
-
French masonic lodge at heart of murky murder trial
-
US military building 'massive complex' beneath White House ballroom project: Trump
-
IPL captain takes pop at Cricket Australia over record-buy Green
-
G7 ministers set to tackle financial fallout of Mideast war
-
Premier League fans feel the pinch from ticket price hikes
-
Australia to halve fuel tax in response to Middle East war
-
Crude surges, stocks dive as Houthi attacks escalate Iran war
-
Air China resumes flights to North Korea after 6-year pause
-
NBA-best Thunder beat Knicks as Boston seal playoff spot
-
Australian fugitive shot dead by police after seven-month manhunt
-
King Kimi, Max misery, Bearman smash: Japan GP talking points
-
Philippines oil refinery secures 2.5 mn barrels of Russian crude
-
Trump says Russia can deliver oil to Cuba
-
All Blacks prop Williams out of Super Rugby season with back infection
-
Life with AI causing human brain 'fry'
-
Dubious AI detectors drive 'pay-to-humanize' scam
-
Test star Carey the hero as South Australia win Sheffield Shield final
-
Defending champ Kim Hyo-joo holds off Korda to win LPGA Ford Championship
-
Implacable Sinner overpowers Lehecka to win Miami Open
-
Australian police shoot dead fugitive wanted for killing officers
Bosses resign at Japan supplement firm probing deaths
The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes 80 deaths potentially linked to tablets meant to lower cholesterol.
Kobayashi Pharmaceutical is at the centre of a health scare linked to its over-the-counter tablets containing red yeast rice, which is fermented with a mould culture.
Medical studies say red yeast rice or "beni koji" can improve cholesterol levels but also warn of a risk of organ damage depending on the ingredient's chemical make-up.
A company statement said president Akihiro Kobayashi and chairman Kazumasa Kobayashi were leaving their posts. Both men belong to the firm's founding family.
The decision was made "to clarify executive responsibility over a series of actions by our company related to the 'beni koji' issue", Kobayashi Pharmaceutical said.
Red yeast rice has been used in food, alcoholic drinks and folk medicine for centuries around East Asia.
The scandal erupted in March when the company, a household name in Japan, recalled three brands of dietary supplements after customers complained of kidney problems.
It later said it had detected a potentially toxic acid produced by the mould at one of its factories, and the government inspected the firm's facilities.
Last month, the company said it was probing a total of 80 deaths possibly connected to its pills, and investigating whether organs other than kidneys were harmed.
But at the time the government called Kobayashi Pharmaceutical's delay in reporting the number of cases under investigation "extremely regrettable".
On Tuesday, the company's board of directors said in a separate statement that they "pray for the souls of those who died... and offer condolences to the bereaved families".
The company's new president is Satoshi Yamane, previously head of sustainability policy, the company said.
Outgoing president Akihiro Kobayashi, who has expressed his intention to take responsibility for any harm caused, will remain in an executive role to manage compensation-related matters, it added.
Kobayashi's red yeast rice supplements are regulated under a system created in 2015 under former premier Shinzo Abe.
Some watchdogs have reportedly expressed concerns that the regulation of these products is not sufficiently stringent and that they do not always have the advertised effects.
P.Hernandez--AT